Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;107(4):786-795.
doi: 10.1002/cpt.1744. Epub 2020 Jan 22.

Beyond the Randomized Clinical Trial: Innovative Data Science to Close the Pediatric Evidence Gap

Sebastiaan C Goulooze  1 , Laura B Zwep  1   2 , Julia E Vogt  3   4 , Elke H J Krekels  1 , Thomas Hankemeier  1 , John N van den Anker  5   6 , Catherijne A J Knibbe  1   7
Affiliations
Review

Beyond the Randomized Clinical Trial: Innovative Data Science to Close the Pediatric Evidence Gap

Sebastiaan C Goulooze et al. Clin Pharmacol Ther. 2020 Apr.

Abstract

Despite the application of advanced statistical and pharmacometric approaches to pediatric trial data, a large pediatric evidence gap still remains. Here, we discuss how to collect more data from children by using real-world data from electronic health records, mobile applications, wearables, and social media. The large datasets collected with these approaches enable and may demand the use of artificial intelligence and machine learning to allow the data to be analyzed for decision making. Applications of this approach are presented, which include the prediction of future clinical complications, medical image analysis, identification of new pediatric end points and biomarkers, the prediction of treatment nonresponders, and the prediction of placebo-responders for trial enrichment. Finally, we discuss how to bring machine learning from science to pediatric clinical practice. We conclude that advantage should be taken of the current opportunities offered by innovations in data science and machine learning to close the pediatric evidence gap.

PubMed Disclaimer

References

    1. Brussee, J.M. et al. Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. Expert Rev. Clin. Pharmacol. 9, 1235-1244 (2016).
    1. Allegaert, K., Simons, S.H.P., Tibboel, D., Krekels, E.H., Knibbe, C.A. & van den Anker, J.N. Non-maturational covariates for dynamic systems pharmacology models in neonates, infants, and children: filling the gaps beyond developmental pharmacology. Eur. J. Pharm. Sci. 109S, S27-S31 (2017).
    1. Krekels, E.H.J., van Hasselt, J.G.C., van den Anker, J.N., Allegaert, K., Tibboel, D. & Knibbe, C.A.J. Evidence-based drug treatment for special patient populations through model-based approaches. Eur. J. Pharm. Sci. 109S, S22-S26 (2017).
    1. Mehrotra, N. et al. Role of quantitative clinical pharmacology in pediatric approval and labeling. Drug Metab. Dispos. 44, 924-933 (2016).
    1. Rostami-Hodjegan, A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin. Pharmacol. Ther. 92, 50-61 (2012).

Publication types